Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review

Table 3

Sensitivity analysis.

Analysis		Sensitivity analysis	I^2	Cochran P	OR (95% CI)
ORR	CRC	REM	57%		2.43 [1.06, 5.60]
	EC		0%		1.85 [1.17, 2.92]
	GC		0%		2.60 [1.78, 3.80]
	LC		0%		1.77 [1.04, 3.03]
DCR	CRC	REM	62%		2.74 [0.85, 8.79]
	EC		0%		1.99 [1.10, 3.58]
	GC		0%		3.17 [1.88, 5.33]
	LC		12%		4.10 [1.99, 8.42]
SR	1-year	REM	53%		2.33 [1.24, 4.73]
	2-year		0%		1.75 [1.15, 2.68]
	3-year		0%		1.86 [1.09, 3.18]
KPS		FEM	0%		2.67 [1.76, 4.03]
Gastrointestinal dysfunction	CRC	REM	0%		0.64 [0.36, 1.16]
	EC		32%		0.62 [0.31, 1.22]
	GC		0%		0.30 [0.19, 0.46]
	LC		65%		0.34 [0.13, 0.92]
The decline of leucocyte count		FEM	0%		0.28 [0.21, 0.38]
Hepatic and renal dysfunction		FEM	5%		0.79 [0.49, 1.29]